Forbes

The Trump administration says it wants more physicians, but its immigration policies have reduced the flow of doctors to the United States.

To understand life in America, we must understand how and when we die. In 2026, it’s not a pretty picture. U.S. health and care is worse than other nations and declining.

Screwworm infections will likely not only damage the beef industry, but can hurt people and pets. Musk's DOGE cut 1/4 of the USDA. How can you protect yourself?

Humana, one of the largest U.S. sellers of Medicare Advantage insurance for older adults, will divest its stake in a provider of end-of-life services for $900 million.

As millions attend the World Cup, health experts are keeping an eye on the spread of infectious diseases. Some are asking, "Do I need to worry about Ebola or hantavirus?"

In this week’s edition of InnovationRx, we look at the AI drug discovery startup Lilly and Pfizer are betting on, the greatest living immigrants in healthcare and more.

Primary care physician compensation reached nearly $330,000 last year but “increases generally trailed the cost of living,” the Medical Group Management Association said.

AI is helping hospitals improve diagnostics and patient care, but it's also giving cybercriminals new tools to target healthcare systems.

An ER doc's guide to the biggest health risks at the 2026 FIFA World Cup. 4 tips on heat, alcohol, vaccines, and how to stay safe across 16 cities this summer.

The Code as Witness written by Steven C. Quay is part scientific investigation, part policy strategy, and part warning about the future of biological research.

How does Medicare approve technology for new patients? What is the alternative NTAP or New Technology Add-on Payment Pathway? And why does Medicare want to repeal it?

Half of U.S. employers and health plans are balking at paying for GLP-1 drugs like Ozempic, Zepbound and Wegovy for weight loss and obesity treatment, a new report shows.

For 14 years, patient access to TAVR has been restricted for Medicare beneficiaries under a Coverage with Evidence Development requirement. This could change by June 15.

The U.S. Ebola response has been reactionary as opposed to proactive. A doctor breaks down why and how it mirrors the U.S. response to COVID-19.